Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity

Myocardial Injury Clinical Trial

Official title:

Impact of Combining N-acetylcysteine Intravenous Infusion and Intralipid Emulsion Infusion Versus Intralipid Infusion Alone on Myocardial Injury in Aluminum Phosphide Toxicity

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05370729
• Other study ID #: NACILEALP
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 2022
• Est. completion date: May 2025

Study information

• Verified date: May 2022
• Source: Assiut University
• Contact: Tassbeeh Kamal
• Phone: 01065656202
• Email: tk.zanaty_92[@]med.aun.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Assess impact of ILE and NAC in morbidity and mortality when used as adjuvant therapy to routine management of acute ALP poisoning.

Description:

Aluminum phosphide (ALP) is one of the solid fumigant pesticides. In Egypt, ALP is extensively used to protect grains against insects and rodents. It is available in the form of tablets known as "grain tablet". Suicidal ingestion of ALP tablets is obviously increasing in developing countries. This is attributed to its wide use, free availability in the market, and its low cost. Aluminum phosphide toxicity is extremely fatal. The conveyed mortality rate differs from 37-100%. More than 90% of patients die within the first 24 hours, mainly due to cardiac dysrhythmia. Despite continuous research, no effective antidote has been reported for this lethal poisoning so far. PH3 is phosphorus trihydride and solubility of phosphorus can affect PH3. Solubilities of phosphorus are as follows: In water: 1 part/300,000 parts water; in absolute alcohol: 1 g/400 mL. One gram phosphorus dissolves in 80 ml olive oil, 60 ml oil of turpentine, and about 100 mL of almond oil. So, PH3 might also have lipid soluble property and used IV lipid emulsion may counter its effects. Intravenous lipid emulsion (ILE) is a sterile fat emulsion prepared for intravenous administration as a source of calories and essential fatty acids. Its main components include up to 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection. In addition, sodium hydroxide has been added to adjust the pH, so that the final pH is 8. Based on animal models and clinical studies, ILE is an established antidote for local-anesthetic drugs systemic toxicity. Besides, ILE has been well used for resuscitation of severe toxicities caused by various lipophilic non-local anesthetic drugs. N-acetylcysteine (NAC) is a well-studied compound which is commonly used in the treatment of paracetamol poisoning. It has shown to replenish cellular glutathione stores in addition to the strong antioxidant properties. NAC has shown to reduce mortality, hospitalization time, and need for mechanical ventilation in ALP poisoning. A cohort study by Agarwal reported survival benefit in patients who received treatment with NAC compared to the control group. Brain natriuretic peptide (BNP) is an excellent biomarker because it can be detected in the early stages of ischemia and decreases shortly after ischemia allowing better detection of re-injury. A metabolite of BNP, Nterminal pro-BNP, NT-proBNP, is relatively easy to measure and predicts short and long term outcomes. BNP is a 32-amino-acid peptide synthesized predominantly from the ventricular myocardium and is released in proportion to the degree of wall stress. Although it has gained recent prominence in the diagnosis and treatment of heart failure, BNP has recently shown promise in predicting the extent of myocardial ischemia in acute coronary syndromes. For instance, the magnitude of BNP released between 1 and 7 days after a myocardial infarction is predictive of left ventricular dysfunction, heart failure, and mortality.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 58
• Est. completion date: May 2025
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Presentation with symptomatic acute ALP poisoning.
• History of exposure including reliable identification of the compound based on the container brought by patient's relatives.
• The suggestive clinical manifestations following shortly after a single exposure to ALP.

Exclusion Criteria:

• Co-ingestion or exposure to other substances in addition to ALP.
• Patients had major medical conditions (e.g., cardiovascular disease, renal or hepatic failure).
• Patients received treatment in any hospital or medical center before admission - other than emergency department of Assiut University Hospital.

Related Conditions & MeSH terms

• Myocardial Injury
• Wounds and Injuries

Intervention

Drug:
• N-acetyl cysteine
Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (4)

Agarwal A, Robo R, Jain N, Gutch M, Consil S, Kumar S. Oxidative stress determined through the levels of antioxidant enzymes and the effect of N-acetylcysteine in aluminum phosphide poisoning. Indian J Crit Care Med. 2014 Oct;18(10):666-71. doi: 10.4103/0972-5229.142176. — View Citation

Baruah U, Sahni A, Sachdeva HC. Successful management of aluminium phosphide poisoning using intravenous lipid emulsion: Report of two cases. Indian J Crit Care Med. 2015 Dec;19(12):735-8. doi: 10.4103/0972-5229.171412. — View Citation

Tehrani H, Halvaie Z, Shadnia S, Soltaninejad K, Abdollahi M. Protective effects of N-acetylcysteine on aluminum phosphide-induced oxidative stress in acute human poisoning. Clin Toxicol (Phila). 2013 Jan;51(1):23-8. doi: 10.3109/15563650.2012.743029. Epub 2012 Nov 14. — View Citation

Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997 Jul 15;96(2):509-16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Echocardiography	Follow up cardiac function by echocardiography focusing on LV EF	24 hours
Secondary	Renal function test	Effect on renal function by measuring serum creatinine and serum BUN	24 hours
Secondary	Total days of ICU stay	ICU stay	Up to two weeks